Skip to content

A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period

A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003230
Enrollment
Unknown
Registered
2020-04-21
Start date
2020-04-25
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel coronavirus pneumonia (COVID-19)

Interventions

Sponsors

Hubei Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the COVID-19 diagnostic criteria and discharge standards with SARS-CoV-2 virus nucleic acid test is negative; 2. The pulmonary imaging in the last 1 week showed inflammation or fibrosis; 3. Aged 18 to 70 years old; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. History of pulmonary surgery which affected lung function; 2. Relying on mechanical ventilation to maintain lung function; 3. Complications of chronic lung disease, such as COPD; 4. Complications affecting heart function; 5. Patients with severe primary diseases may affect participation in the trial or may affect the outcome of the study by the judgment of the researcher; 6. Resting heart rate >120/min; 7. Systolic blood pressureda>180mmHgDiastolic blood pressure>100mmHg; 8. Unstable angina or myocardial infarction that occurred within the past month; 9. BMI>40; 10. Patients who are allergic constitution or allergy to multiple drug; 11. Pregnant or lactating women; 12. Handicapped who can't complete the collection of efficacy evaluation indicators; 13. Patients who have a family history of mental illness or have had a mental illness; 14. Patients who are participating in other clinical trials; 15. According to the investigator's judgment, patients who have complicated enrollment or poor compliance, which affect the efficacy and safety assessment.

Design outcomes

Secondary

MeasureTime frame
GAD-7;PHQ-9;SARS-CoV-2 nucleic acid test and 2019-nCoV Antibody Test ;QQL-BREF;Clinical symptoms;Dynamic oxygen saturation;

Primary

MeasureTime frame
Six-minute Walk Test;lung CT;

Countries

China

Contacts

Public ContactXiao Mingzhong

Hubei Provincial Hospital of TCM

309452513@qq.com+86 18908640865

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026